Clinical trial
Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients…
NCT04745832 · MEI Pharma, Inc., Industry · Terminated
Key facts
| NCT number | NCT04745832 |
|---|---|
| Title | Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL) |
| Official title | A Phase 3, Randomized, Open-Label, Controlled, Multicenter Study of Zandelisib (ME- 401) in Combination With Rituximab Versus Standard Immunochemotherapy in Patients With Relapsed Indolent Non Hodgkin's Lymphoma (iNHL) - The COASTAL Study |
| Lead sponsor | MEI Pharma, Inc., Industry |
| Collaborators | Kyowa Kirin, Inc. Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Follicular Lymphoma (FL), Non Hodgkin Lymphoma, Marginal Zone Lymphoma |
| Intervention type | Drug |
| Interventions | Zandelisib, Rituximab, Bendamustine, CHOP |
| Enrollment | 82 |
| Start date | Aug 13, 2021 |
| Primary completion | Mar 20, 2023 |
| Completion | Mar 20, 2023 |
| First posted | Feb 9, 2021 |
| Last update posted | Nov 4, 2024 |
| Countries | Australia, Belgium, Canada, France, Georgia, Greece, Hungary, Italy, Japan, Netherlands, New Zealand, Poland and 7 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: